Next-generation sequencing (NGS) is any of several high throughput approaches of DNA sequencing using the concept of massively parallel processing. Many NGS platforms differ on the basis of engineering configurations and sequencing chemistry. They share the technical paradigm of massively parallel sequencing via spatially separated, clonally amplified DNA templates or single DNA molecules in a flow cell. NGS is also known as capillary sequencing, massively parallel sequencing, or massively parallel sequencing. Next-generation sequencing technologies are currently used for whole-genome sequencing, investigation of genome diversity, epigenetic, metagenomics, identification of non-coding RNAs and protein binding sites, and gene expression profiling by RNA sequencing.
Global Next Generation Sequencing Market is valued at USD 8156.4 Million in 2020 and is expected to reach USD 26762.5 Million by 2027 with a CAGR of 18.5% over the forecast period.
These are also used in microbiology and virology for detecting various microorganisms and viruses by using metagenomic approaches, investigating microbial communities in the human bodies and environment. And, it is also used for the analysis of viral genome variability within the host and detection of low abundance antiviral drug resistance mutations in HIV patients. Some of these sequencing technologies emerged in 1994-1998 and have been commercially available since 2005.
Thermo Fisher Scientific is an American supplier of scientific instruments, reagents, consumables, and software services. Headquartered in Waltham, Mass., Thermo Fisher was born from the merger of Thermo Electron and Fisher Scientific in 2006. Thermo Fisher has acquired other suppliers of reagents, consumables, instruments and services, including: Life Technologies Corporation, Alfa Aesar, Affymetrix, FEI Company & BD. In March 2020, Thermo Fisher received emergency use authorization from the FDA to test for SARSCoV2 to help mitigate the COVID19 pandemic.
Thermo Fisher Scientific had nearly 80,000 Employees and had revenue of $ 32 Billion.
Illumina, Inc. is an American corporation. Founded on April 1, 1998, Illumina develops, manufactures, and markets integrated systems for the analysis of genetic variation and biological function. The company offers a wide range of products and services for sequencing, genotyping, and expression, as well as protein markets. Its headquarters are located in San Diego, California.
Illumina had nearly 7,800 Employees and had revenue of $ 3 Billion.
PerkinElmer, Inc., formerly PerkinElmer, is an American global company specializing in diagnostics, life science research, food testing, environmental and industrial testing. Its capabilities include detection, imaging, computation, and services. PerkinElmer manufactures analytical instruments, genetic testing, and diagnostic tools, medical imaging components, software, instruments, and consumables for a number of end markets. PerkinElmer is part of the S&P 500 Index and operates in 150 countries.
PerkinElmer had nearly 14,000 Employees and had revenue of $ 3 Billion.
BGI, now known as BGI Group, formerly known as Beijing Genomics Institute, is a Chinese genome sequencing company with headquarters in Shenzhen, Guangdong, China. It was established in 1999 to participate in the Human Genome Project as a center for genetic research. It also sequenced the genomes of other animals, plants, and microorganisms. The company has grown from a research institute that decodes the DNA of pandas and rice plants to a company specializing in animal cloning, health screening, and contract research, while his previous research at non-profit organizations is continued by the Beijing Institute of Genomics, Chinese Academy of Sciences. spun off in 2006, along with non-profit affiliates BGI Research and National GeneBank of China.
BGI Group had nearly 6,000 Employees and had revenue of $ 368 Million.
Hoffmann La Roche AG, commonly known as Roche, is a Swiss multinational healthcare company operating worldwide under two divisions: Pharmaceuticals and Diagnostics. Its parent company, Roche Holding AG, holds anonymous shares listed on the Swiss Exchange SIX. The company's headquarters is located in Basel. Roche is the world's largest pharmaceutical company and the world's leading supplier of cancer treatments.
Roche had nearly 100,000 Employees and had revenue of $ 63 Billion.
BioRad Laboratories, Inc. is an American developer and manufacturer of specialty technology products for the clinical diagnostic and life science research markets. The company was founded in 1952 in Berkeley, California by husband and wife team David and Alice Schwartz, both graduates of the University of California at Berkeley. BioRad is headquartered in Hercules, California, and does business around the world. BioRad's life science products mainly include instruments, software, consumables, reagents, and content for the fields of cell biology, gene expression, protein purification, protein quantification, drug discovery and production, science education, and food safety.
Bio-Rad Laboratories had nearly 7,800 and had revenue of $ 2 Billion.
QIAGEN is a German supplier of sampling and testing technology for molecular diagnostics, applied testing, academic research, and pharmaceuticals. Consolidated under the parent company QIAGEN N.V. of the Netherlands, the company operates more than 35 offices in more than 25 countries. QIAGEN shares are listed on the NYSE (using the ticker QGEN) and the Frankfurt Stock Exchange under Prime standards (using the ticker QIA). The headquarters of operations are located in Hilden, Germany.
Qiagen had nearly 4,700 Employees and had revenue of $ 993 Million.